CN107296793A - 适于治疗或预防结核的脂质体制剂 - Google Patents

适于治疗或预防结核的脂质体制剂 Download PDF

Info

Publication number
CN107296793A
CN107296793A CN201710129725.4A CN201710129725A CN107296793A CN 107296793 A CN107296793 A CN 107296793A CN 201710129725 A CN201710129725 A CN 201710129725A CN 107296793 A CN107296793 A CN 107296793A
Authority
CN
China
Prior art keywords
tuberculosis
liposome
fcmtb
formulation
mycobacterium tuberculosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710129725.4A
Other languages
English (en)
Chinese (zh)
Inventor
佩尔·乔娜·卡唐娜·伊杰勒塞斯
伊莎贝尔·艾玛特·里拉
布兰卡·雷耶斯
艾瑞德纳·瑟格
梅尔斯·艾玛特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Archivel Farma SL
Original Assignee
Archivel Farma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11150072A external-priority patent/EP2471511A1/en
Application filed by Archivel Farma SL filed Critical Archivel Farma SL
Publication of CN107296793A publication Critical patent/CN107296793A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201710129725.4A 2011-01-04 2012-01-04 适于治疗或预防结核的脂质体制剂 Pending CN107296793A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11150072.4 2011-01-04
EP11150072A EP2471511A1 (en) 2011-01-04 2011-01-04 Liposome formulation suitable for treating or preventing tuberculosis
EP11183487.5 2011-09-30
EP11183487 2011-09-30
CN201280011787.0A CN103796640A (zh) 2011-01-04 2012-01-04 适于治疗或预防结核的脂质体制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280011787.0A Division CN103796640A (zh) 2011-01-04 2012-01-04 适于治疗或预防结核的脂质体制剂

Publications (1)

Publication Number Publication Date
CN107296793A true CN107296793A (zh) 2017-10-27

Family

ID=45509459

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710129725.4A Pending CN107296793A (zh) 2011-01-04 2012-01-04 适于治疗或预防结核的脂质体制剂
CN201280011787.0A Pending CN103796640A (zh) 2011-01-04 2012-01-04 适于治疗或预防结核的脂质体制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280011787.0A Pending CN103796640A (zh) 2011-01-04 2012-01-04 适于治疗或预防结核的脂质体制剂

Country Status (18)

Country Link
US (1) US9877917B2 (enExample)
EP (1) EP2661253B1 (enExample)
JP (1) JP6096675B2 (enExample)
KR (1) KR101820026B1 (enExample)
CN (2) CN107296793A (enExample)
BR (1) BR112013017267B1 (enExample)
CA (1) CA2823747C (enExample)
CO (1) CO6801728A2 (enExample)
ES (1) ES2631556T3 (enExample)
HU (1) HUE032409T2 (enExample)
IL (1) IL227338B (enExample)
LT (1) LT2661253T (enExample)
MX (1) MX341918B (enExample)
PL (1) PL2661253T3 (enExample)
RU (1) RU2648842C2 (enExample)
SI (1) SI2661253T1 (enExample)
WO (1) WO2012093137A1 (enExample)
ZA (1) ZA201305697B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109675059A (zh) * 2019-01-23 2019-04-26 青岛大学 一种类杆菌脂质体及其制备方法与应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103720657B (zh) * 2013-11-19 2017-01-04 广东丸美生物技术股份有限公司 一种可变形脂质体的制备方法，及其制备的可变性脂质体
JP2016163851A (ja) * 2015-03-06 2016-09-08 国立大学法人福井大学 コンポジット型可溶化ナノリポソーム及びその製造方法
RU2631607C1 (ru) * 2016-11-22 2017-09-25 Владислав Николаевич Ласкавый Средство для профилактики лейкоза крупного рогатого скота и способ его применения
GB201707700D0 (en) * 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
US11202823B2 (en) * 2019-04-05 2021-12-21 Northwestern University Multi-subunit vaccines to elicit both MHC- and CD1-restricted T cell responses
CN120456894A (zh) * 2021-10-14 2025-08-08 爱琴韦尔制药公司 用于治疗活动性结核病的脂质体制剂
CN115850520A (zh) * 2022-12-12 2023-03-28 中国农业大学 新型结核病亚单位疫苗al的制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1874785A (zh) * 2003-10-31 2006-12-06 爱琴韦尔制药公司 用于与其它药物一起联合治疗结核的免疫治疗剂
CN101283085A (zh) * 2005-08-11 2008-10-08 哈佛大学的校长及成员们 用于干燥细胞形式的方法和组合物
WO2009073941A2 (en) * 2007-12-12 2009-06-18 Universidade Estadual De Campinas-Unicamp Ternary liposomal composition containing a polynucleotide
CN101600455A (zh) * 2006-10-30 2009-12-09 阿尔西维尔法尔玛公司 预防性结核疫苗

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU720288B2 (en) 1995-02-22 2000-05-25 Adcock Ingram Limited A method for the isolation and purification of lipid cell-wall components
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
CA2453173C (en) 2001-07-04 2013-12-10 Health Protection Agency Mycobacterial antigens expressed during latency
BR0103887C1 (pt) * 2001-07-17 2005-11-08 Univ Minas Gerais Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
EP1761662A4 (en) 2004-07-01 2010-02-03 Univ California PROTEOMICS WITH HIGH THROUGHPUT
SI2457926T1 (sl) 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Nov postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis
WO2007022152A2 (en) * 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
WO2008051245A2 (en) 2005-12-02 2008-05-02 Novartis Ag Nanoparticles for use in immunogenic compositions
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US20090081284A1 (en) 2006-04-20 2009-03-26 Tokai University Educational System Therapeutic agent for allergy containing liposome having oligosaccharide on its surface
EP2076244B1 (en) 2006-10-10 2016-12-07 Jina Pharmaceuticals Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
US8741313B2 (en) * 2008-01-11 2014-06-03 Emory University Polypeptide vaccine and vaccination strategy against mycobacterium
ES2335177B1 (es) 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
KR20170072366A (ko) * 2009-04-24 2017-06-26 스태튼스 세룸 인스티튜트 재활성화를 예방하기 위한 결핵 백신
DK2651436T3 (da) 2010-12-14 2016-06-20 Glaxosmithkline Biologicals Sa Mycobakterie antigen sammensætning.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1874785A (zh) * 2003-10-31 2006-12-06 爱琴韦尔制药公司 用于与其它药物一起联合治疗结核的免疫治疗剂
CN101283085A (zh) * 2005-08-11 2008-10-08 哈佛大学的校长及成员们 用于干燥细胞形式的方法和组合物
CN101600455A (zh) * 2006-10-30 2009-12-09 阿尔西维尔法尔玛公司 预防性结核疫苗
WO2009073941A2 (en) * 2007-12-12 2009-06-18 Universidade Estadual De Campinas-Unicamp Ternary liposomal composition containing a polynucleotide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
张静等: "脂质体的液晶态结构和稳定性研究", 《液晶与显示》 *
朱孝祖等: "脂质体载抗结核药治疗小鼠结核的疗效观察", 《铁植医学》 *
韩翠艳主编: "《药物制剂技术》", 31 August 2008, 哈尔滨工程大学出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109675059A (zh) * 2019-01-23 2019-04-26 青岛大学 一种类杆菌脂质体及其制备方法与应用

Also Published As

Publication number Publication date
US9877917B2 (en) 2018-01-30
ES2631556T3 (es) 2017-09-01
IL227338A0 (en) 2013-09-30
IL227338B (en) 2019-01-31
CA2823747C (en) 2019-07-23
CO6801728A2 (es) 2013-11-29
MX2013007855A (es) 2013-10-25
SI2661253T1 (sl) 2017-07-31
ZA201305697B (en) 2014-07-30
BR112013017267B1 (pt) 2021-06-22
CA2823747A1 (en) 2012-07-12
KR101820026B1 (ko) 2018-01-18
WO2012093137A1 (en) 2012-07-12
EP2661253B1 (en) 2017-04-19
RU2013136379A (ru) 2015-02-10
EP2661253A1 (en) 2013-11-13
KR20140021538A (ko) 2014-02-20
MX341918B (es) 2016-09-07
JP2014501768A (ja) 2014-01-23
HUE032409T2 (en) 2017-09-28
BR112013017267A2 (pt) 2018-01-09
JP6096675B2 (ja) 2017-03-15
RU2648842C2 (ru) 2018-03-28
BR112013017267A8 (pt) 2018-11-06
CN103796640A (zh) 2014-05-14
LT2661253T (lt) 2017-05-25
US20150050327A1 (en) 2015-02-19
WO2012093137A9 (en) 2012-12-27
PL2661253T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
US9877917B2 (en) Liposome formulation suitable for treating or preventing tuberculosis
RU2526910C2 (ru) Профилактическая вакцина от туберкулеза
WO2017196979A1 (en) Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
CN106456739A (zh) 用于诱导免疫应答的新方法
US8795719B2 (en) Immunotherapeutic agent suitable for the primary prophylaxis of tuberculosis
DK2802345T3 (en) MTB-C-VACCINE AGAINST ALLERGIC REACTIONS
Trentini et al. Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection
WO2020094580A1 (en) Immunogenic compositions
CN120456894A (zh) 用于治疗活动性结核病的脂质体制剂
EP2471511A1 (en) Liposome formulation suitable for treating or preventing tuberculosis
US20260137766A1 (en) Liposome formulations for treatment of active tuberculosis
HK1171659A (en) Liposome formulation suitable for treating or preventing tuberculosis
EA053229B1 (ru) Применение липосомных композиций для лечения активной формы туберкулеза
WO2025191183A1 (en) Liposome formulations for the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20171027

RJ01 Rejection of invention patent application after publication